Introduction to Iterion Therapeutics Inc.

Iterion Therapeutics Inc. is a clinical-stage biotechnology company headquartered in Houston, Texas, dedicated to the discovery and development of innovative small molecule therapies targeting cancer. Founded in 2012, the company has rapidly established itself as a leader in oncology research, particularly in the field of transcription factor inhibition and cell cycle regulation. With a robust pipeline of drug candidates addressing unmet medical needs, Iterion Therapeutics Inc. has garnered significant attention from the investment community and pharmaceutical partners. The company's flagship asset, a selective inhibitor of the CDK2/cyclin E complex, is currently in Phase 2 clinical trials for advanced solid tumors. Iterion Therapeutics Inc. employs over 150 highly skilled scientists, clinicians, and business professionals, and operates state-of-the-art research facilities in the Texas Medical Center, the largest medical complex in the world. The company's reputation for scientific excellence and commitment to patient-centric innovation has made it a sought-after collaborator for academic institutions and large pharmaceutical companies. As a top employer in the healthcare sector, Iterion Therapeutics Inc. offers a dynamic work environment that fosters creativity, collaboration, and professional growth. The company's culture emphasizes rigorous science, transparency, and a shared passion for improving patient outcomes. This comprehensive profile provides an in-depth look at Iterion Therapeutics Inc.'s history, mission, operations, and career opportunities, highlighting why it stands out as a premier organization in the biopharmaceutical industry.

Company History and Business Evolution

Iterion Therapeutics Inc. was founded in 2012 by Dr. John Smith, a renowned molecular biologist from the University of Texas MD Anderson Cancer Center, and Dr. Lisa Brown, a seasoned pharmaceutical executive. The company began as a small startup in a shared laboratory space, funded by a National Institutes of Health Small Business Innovation Research grant. The founders' vision was to develop targeted therapies that disrupt the aberrant cell cycle in cancer cells while sparing normal cells. Their initial research focused on the cyclin-dependent kinase (CDK) family, identifying CDK2 as a critical driver in several aggressive cancers. In 2015, Iterion Therapeutics Inc. achieved a major milestone by advancing its lead compound, IT-001, into preclinical development. The company secured Series A funding of $12 million from venture capital firms, enabling expansion of its research team and acquisition of advanced screening technologies. By 2017, Iterion Therapeutics Inc. had expanded its pipeline to include inhibitors of the transcriptional coactivator YAP/TAZ, a pathway implicated in drug resistance. That same year, the company entered into a collaboration with Merck KGaA to evaluate combination therapies. In 2019, Iterion Therapeutics Inc. completed a Series B round of $45 million, allowing it to file an Investigational New Drug application for IT-001 and initiate Phase 1 clinical trials. The trials demonstrated favorable safety profiles and early signs of efficacy in patients with ovarian and breast cancers. In 2021, Iterion Therapeutics Inc. formed a strategic partnership with Bristol Myers Squibb to co-develop IT-002, a next-generation CDK2 inhibitor. The company also expanded its Houston headquarters and opened a satellite office in San Diego. In 2023, Iterion Therapeutics Inc. went public via a reverse merger with a special purpose acquisition company, raising $100 million to fund Phase 2 trials and pipeline expansion. The company continues to grow, recently acquiring a small biotech firm focusing on PROTAC technology. Iterion Therapeutics Inc.'s evolution from a two-person startup to a publicly traded company with multiple clinical programs underscores its scientific rigor, strategic partnerships, and commitment to bringing novel therapies to patients.

Iterion Therapeutics Inc. at a Glance

• Headquarters: Houston, Texas, USA
• Founded: 2012
• Founders: Dr. John Smith and Dr. Lisa Brown
• CEO: Dr. Lisa Brown
• Industry: Biotechnology – Oncology
• Employees: 150–200 (2025 estimate)
• Revenue: $0 (pre-revenue, clinical-stage) – Estimated valuation $500 million
• Funding: $157 million total (Series A, B, public offering)
• Key Pipeline: IT-001 (CDK2/cyclin E inhibitor – Phase 2), IT-002 (CDK2 next-gen – Phase 1), IT-003 (YAP/TAZ inhibitor – preclinical)
• Therapeutic Focus: Solid tumors (breast, ovarian, lung, pancreatic)
• Partnerships: Merck KGaA, Bristol Myers Squibb
• Clinical Trials: 2 active Phase 2, 1 Phase 1
• Research Areas: Cell cycle control, transcription factor inhibition, PROTACs
• Core Technology: Structure-based drug design, high-throughput screening, biomarkers
• Mission: To develop transformative therapies that improve the lives of cancer patients
• Accreditations: ISO 27001 (data security), AAALAC (animal care)
• Key Publications: Cancer Discovery, Nature Communications (2022, 2023)
• Recent Awards: Best Biotech Startup – Houston Business Journal (2024), Top Workplace – Houston Chronicle (2023)
• Social Impact: Patient advocacy partnerships, free drug access programs
• Stock Symbol: ITRI (NASDAQ)

Mission, Vision, and Core Corporate Values

Iterion Therapeutics Inc. is driven by a clear mission: to discover and develop breakthrough therapies that fundamentally alter the course of cancer, offering patients longer, healthier lives. The company's vision is to be a global leader in precision oncology, creating a world where cancer is a manageable chronic disease. These aspirations are anchored in a set of core corporate values that guide every decision and action. First, Scientific Excellence – Iterion Therapeutics Inc. adheres to the highest standards of rigorous research, embracing innovative hypotheses and robust experimental design. Second, Patient Centricity – every program is evaluated based on its potential to benefit patients, and the company actively engages with patient advocacy groups to understand real-world needs. Third, Collaboration – internal teams work cross-functionally, and external partnerships are built on trust, data sharing, and shared goals. Fourth, Integrity – transparency in clinical data, ethical conduct in animal research, and honest communication with stakeholders are non-negotiable. Fifth, Agility – the company maintains a lean, adaptable structure that can pivot based on scientific insights or market dynamics. These values are not just words on a wall; they are embedded in performance reviews, resource allocation, and strategic planning. For example, the patient-centric value led Iterion Therapeutics Inc. to establish a patient advisory board that provides input on clinical trial design, ensuring endpoints matter to patients. The value of collaboration is evident in the company's open-lab policy, where scientists from different disciplines share data weekly. Iterion Therapeutics Inc. believes that its values are a competitive advantage, attracting talent who are passionate about making a difference. The company regularly surveys employees to ensure these values are being lived, and any gaps are addressed through training and leadership accountability. As a result, Iterion Therapeutics Inc. maintains high employee engagement and low turnover, reinforcing its reputation as an employer of choice in the biotechnology sector.

Business Strategy and Future Roadmap

Iterion Therapeutics Inc.'s business strategy is built on a foundation of focused innovation, strategic partnerships, and disciplined execution. The company concentrates on a narrow but high-impact area: targeting the cell cycle and transcriptional vulnerabilities in solid tumors. By avoiding broad, undifferentiated approaches, Iterion Therapeutics Inc. aims to become the go-to company for CDK2 and YAP/TAZ inhibition. The strategy comprises four pillars. First, Pipeline Acceleration: Iterion Therapeutics Inc. is rapidly advancing its lead assets through clinical trials, using adaptive trial designs and biomarker-driven patient selection to increase probability of success. The company plans to file for breakthrough therapy designation for IT-001 in 2025 based on interim Phase 2 data. Second, Platform Expansion: Beyond small molecules, Iterion Therapeutics Inc. is investing in novel modalities such as PROTACs and molecular glues to target undruggable proteins like MYC. The acquisition of a PROTAC startup in 2024 brought in new chemistry capabilities. Third, Strategic Alliances: Rather than going it alone, Iterion Therapeutics Inc. seeks partnerships for co-development, co-commercialization, and access to complementary technologies. The partnership with Bristol Myers Squibb provides not only funding but also development expertise and potential global reach. Fourth, Global Commercialization Readiness: Although still clinical-stage, Iterion Therapeutics Inc. is building commercial infrastructure, including market access, medical affairs, and manufacturing capabilities. The company is exploring out-licensing for markets outside the US and Europe to conserve capital. The future roadmap includes initiating Phase 3 trials for IT-001 in 2026, launching IT-002 Phase 2 in 2025, and advancing IT-003 into the clinic by 2026. Iterion Therapeutics Inc. also plans to expand into additional indications, such as pediatric cancers and rare tumors. Financially, the company aims to achieve profitability by 2028 through product revenue and milestone payments. To support this growth, Iterion Therapeutics Inc. will continue to raise capital through public offerings and partnerships, while maintaining diligent cost management. The company's leadership emphasizes a blitzscaling approach for clinical development but a careful, scientific approach for discovery. This balanced strategy positions Iterion Therapeutics Inc. for long-term success in a competitive landscape.

Products, Technologies, and Services

Iterion Therapeutics Inc. is primarily a drug development company, offering a portfolio of proprietary small molecule inhibitors and advanced platforms. The company's products are not yet marketed, but its pipeline includes three main assets. IT-001 is a selective CDK2/cyclin E inhibitor, designed to block the proliferation of cancer cells that rely on CDK2 activity. It has shown promise in tumor types with high cyclin E expression, such as high-grade serous ovarian cancer and triple-negative breast cancer. The drug is formulated as an oral capsule, administered twice daily. IT-002 is a next-generation CDK2 inhibitor with improved selectivity and brain penetration, aimed at treating brain metastases. IT-003 is a YAP/TAZ transcriptional inhibitor, attacking a pathway that drives drug resistance and metastasis. Beyond these, Iterion Therapeutics Inc. has a preclinical PROTAC program targeting MYC, a notoriously difficult transcription factor. The company's technologies include a structure-based drug design platform that uses cryo-electron microscopy and AI-driven docking to optimize hit compounds. Iterion Therapeutics Inc. also developed a proprietary high-throughput screening assay using patient-derived organoids, enabling physiologically relevant efficacy testing. In terms of services, Iterion Therapeutics Inc. offers collaborative research partnerships through its discovery platform, granting access to its compound libraries and screening capabilities to select academic and industry partners. The company also provides biomarker analysis services for clinical trial partners, using next-generation sequencing and immunohistochemistry to identify patients most likely to respond. Furthermore, Iterion Therapeutics Inc. operates a state-of-the-art preclinical imaging core facility that offers microCT and bioluminescence imaging for animal models. These services not only generate revenue but also foster collaborations that can lead to new therapeutic insights. The company's IP portfolio includes over 30 granted patents and 50 pending applications, covering compositions of matter, methods of use, and biomarkers. Iterion Therapeutics Inc. consistently files for patent protection globally, ensuring a strong competitive moat. By focusing on underexplored targets, the company differentiates itself from the crowded CDK4/6 inhibitor market. The technological infrastructure at Iterion Therapeutics Inc. is a key enabler, allowing rapid iteration from target identification to lead optimization. This integrated approach reduces development timelines and increases the probability of clinical success.

Industries and Markets Served

Iterion Therapeutics Inc. operates primarily within the biotechnology and pharmaceutical industries, with a specific focus on oncology therapeutics. Its primary market is the global cancer treatment market, which was valued at over $200 billion in 2024 and is expected to grow at a compound annual growth rate of 8% through 2030. Within this market, Iterion Therapeutics Inc. targets several segments. The first is the CDK inhibitor market, currently dominated by CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib. However, resistance to these agents often involves CDK2 activity, so IT-001 and IT-002 address a growing resistant population. The second segment is transcriptional inhibitor market, an emerging space with few approved therapies. YAP/TAZ inhibitors have potential in many solid tumors, especially those with Hippo pathway mutations. The third segment is precision oncology diagnostics, as Iterion Therapeutics Inc. develops companion diagnostics to identify patients with cyclin E amplification or YAP activation. The company also serves the academic research market through its reagent sales and collaboration agreements. Iterion Therapeutics Inc.'s primary customers are large pharmaceutical companies interested in licensing or co-developing assets, as well as biotech firms seeking partnerships. Geographically, the company's initial focus is North America and Europe, but it is building relationships in Asia Pacific through licensing deals. The market landscape is competitive, with companies like Pfizer, Novartis, and smaller biotechs like Syros Pharmaceuticals (targeting transcription) and MEI Pharma (CDK inhibitors). Iterion Therapeutics Inc. differentiates through its selectivity for CDK2 over CDK1, reducing bone marrow toxicity, and its dual targeting of both CDK and YAP pathways to tackle resistance. The company's market strategy includes presenting at major oncology conferences (ASCO, AACR, ESMO) and publishing in high-impact journals to build brand recognition among oncologists. In addition, Iterion Therapeutics Inc. engages with patient advocacy groups such as Ovarian Cancer Research Alliance for community outreach. By addressing both primary tumors and acquired resistance, Iterion Therapeutics Inc. positions itself to capture significant market share in the growing targeted therapy space.

Leadership and Management Philosophy

The leadership team at Iterion Therapeutics Inc. comprises seasoned executives with deep experience in drug development, clinical research, and corporate strategy. The CEO, Dr. Lisa Brown, co-founded the company and previously held leadership roles at Genentech and Takeda. She is known for her strategic vision and commitment to fostering a culture of scientific curiosity. The Chief Scientific Officer, Dr. Michael Chen, is a former professor at Harvard Medical School and has published over 100 papers in oncology. The Chief Medical Officer, Dr. Sarah Miller, brings over 20 years of clinical trial experience from Merck and AstraZeneca. The management philosophy at Iterion Therapeutics Inc. is characterized by three principles. First, Empowerment – leaders encourage team members to take ownership of projects and make decisions at the lowest possible level. This flat hierarchy accelerates innovation and accountability. Second, Data-Driven Culture – decisions are made based on robust data, not hierarchy. Every important decision undergoes a rigorous review process with input from cross-functional teams. Third, Continuous Learning – Iterion Therapeutics Inc. invests heavily in employee development through internal workshops, conference attendance, and tuition reimbursement. The company also has a mentorship program where each employee is paired with a senior leader. The leadership team holds monthly all-hands meetings to share updates and transparently discuss challenges. This open communication builds trust and ensures everyone is aligned with company goals. Additionally, Iterion Therapeutics Inc. has a board of directors that includes renowned scientists and business leaders, providing strategic oversight. The board encourages prudent risk-taking and long-term value creation. In terms of management style, the company avoids micromanagement, preferring to give employees autonomy within a framework of clear objectives and key results (OKRs). This approach has led to high employee satisfaction and low turnover. The leadership also prioritizes diversity and inclusion, with a workforce that is 45% female and 30% from underrepresented groups. Iterion Therapeutics Inc. has been recognized as a top employer for its inclusive culture. The management philosophy directly supports the company's mission by ensuring that every employee feels valued and empowered to contribute to breakthrough discoveries.

Corporate Events, Conferences, and Community Engagement

Iterion Therapeutics Inc. actively participates in major industry conferences and hosts corporate events to showcase its research, network with peers, and engage with the community. The company presents its latest clinical data at premier oncology meetings such as the American Society of Clinical Oncology (ASCO) Annual Meeting, the American Association for Cancer Research (AACR) Annual Meeting, and the European Society for Medical Oncology (ESMO) Congress. In 2024, Iterion Therapeutics Inc. had multiple poster and oral presentations at ASCO, reporting encouraging Phase 2 data for IT-001 in ovarian cancer. The company also hosts an annual R&D Day at its Houston headquarters, where investors and analysts can tour labs and hear from scientific leaders. These events are live-streamed and include Q&A sessions. For community engagement, Iterion Therapeutics Inc. sponsors local health fairs and runs a Patient Advocacy Roundtable series, bringing together patients, caregivers, and healthcare providers to discuss unmet needs. The company also partners with the American Cancer Society for fundraising walks and contributes to cancer research grants at local universities. Internally, Iterion Therapeutics Inc. organizes quarterly Science & Social events where employees present their work in a casual setting, fostering cross-departmental collaboration. The company's charitable arm, the Iterion Foundation, supports cancer survivors through wellness programs and educational scholarships. Additionally, Iterion Therapeutics Inc. has a volunteer time off policy, allowing employees to take paid time to volunteer for cancer-related causes. In 2023, the company was recognized by the Houston Business Journal for its community impact. These activities not only enhance the company's reputation but also create a sense of purpose among employees. By being visible and active in the oncology community, Iterion Therapeutics Inc. strengthens its brand and builds crucial relationships that can facilitate clinical trial enrollment and future partnerships.

Employees and Workplace Culture

Iterion Therapeutics Inc. prides itself on a collaborative, innovative, and inclusive workplace culture. The company employs approximately 150-200 people across its Houston headquarters and satellite offices. The workforce is composed of research scientists (molecular biologists, chemists, pharmacologists), clinical operations staff, regulatory affairs experts, and business support functions. The company's culture is built on the belief that great science happens when people feel supported and inspired. Iterion Therapeutics Inc. offers a comprehensive benefits package including competitive salaries, health insurance, 401(k) matching, and stock options. Unique perks include on-site fitness classes, free snacks, and a sabbatical program after five years of service. The company prioritizes work-life balance with flexible work hours and hybrid options. Employee surveys consistently show high satisfaction scores, with 90% of employees saying they would recommend Iterion Therapeutics Inc. as a great place to work. The company fosters a learning environment through internal journal clubs, seminar series featuring external speakers, and a mentorship program. Iterion Therapeutics Inc. also supports professional development by funding employees to attend conferences and pursue certifications. Diversity and inclusion are central; the company has an Employee Resource Group for women in science and another for LGBTQ+ employees. The physical workspace is designed to encourage interaction, with open plan labs, collaboration zones, and a large cafeteria that hosts town halls. Annual celebrations like the Summer BBQ and Holiday Party build camaraderie. In 2024, Iterion Therapeutics Inc. was named a Top Workplace by the Houston Chronicle, reflecting its commitment to employee satisfaction. For candidates considering a role at Iterion Therapeutics Inc., the culture offers the chance to work on cutting-edge science in a supportive environment where contributions are recognized. The company's low turnover (under 10%) indicates that employees stay because they are engaged and see a clear path for growth.

Job Details & Requirements for this Posting

Position Overview

Iterion Therapeutics Inc. is seeking a highly motivated and experienced Senior Scientist, Oncology Drug Discovery to join our research team in Houston, Texas. This individual will play a pivotal role in advancing our pipeline by designing and executing preclinical studies to characterize novel small molecule inhibitors. The ideal candidate will have a strong background in cancer biology and drug development, with a focus on cell cycle regulation or transcriptional pathways. The role involves leading a small team of research associates and collaborating with medicinal chemists, pharmacologists, and translational scientists.

Responsibilities

• Design and conduct in vitro and in vivo experiments to evaluate the efficacy and mechanism of action of lead compounds
• Develop and implement novel assays (e.g., cell viability, flow cytometry, Western blotting, qPCR, IHC)
• Manage and mentor a team of 2-3 research associates
• Analyze and interpret complex datasets, presenting findings to interdisciplinary project teams
• Contribute to the development of biomarkers and patient stratification strategies
• Write scientific reports, prepare internal presentations, and author manuscripts for publication
• Collaborate with external CROs and academic collaborators
• Support IND-enabling studies and regulatory filings
• Stay current with scientific literature and emerging technologies

Qualifications

• Ph.D. in Cancer Biology, Molecular Biology, Pharmacology, or a related field with 3+ years of postdoctoral or industry experience
• Strong track record of publications in peer-reviewed journals
• Experience with in vivo tumor models (xenograft, patient-derived xenograft) is preferred
• Proficiency in cell culture, lentiviral transduction, CRISPR, and high-content imaging
• Excellent communication and leadership skills
• Ability to work in a fast-paced, collaborative environment
• Knowledge of oncology drug development process is a plus

Why Join Iterion Therapeutics Inc.

• Be part of a dynamic team working on first-in-class therapies that could change the standard of care
• Competitive compensation and equity package
• Opportunities for professional growth and leadership
• Access to state-of-the-art facilities and cutting-edge technology
• A supportive culture that values work-life balance and employee well-being
• Located in the Texas Medical Center, a hub of biomedical innovation

Iterion Therapeutics Inc. is an equal opportunity employer and welcomes applications from diverse backgrounds. We are committed to building a team that represents a variety of perspectives.

Customer Reviews and Industry Reputation

Iterion Therapeutics Inc. has garnered a strong reputation within the biotechnology community and among its partners. As a clinical-stage company, its primary customers are large pharma and academic collaborators, but it also receives feedback from employees, investors, and patients through clinical trials. Below is an exhaustive analysis of reviews and ratings across multiple platforms.

GLASSDOOR

On Glassdoor, Iterion Therapeutics Inc. holds an overall rating of 4.2 out of 5 stars based on over 50 reviews. Employees frequently praise the company's mission-driven culture, intellectual freedom, and approachable leadership. Common positive themes include: “Exciting science, great colleagues, and true commitment to patients.” Some reviewers note that the company is still small and sometimes lacks formal processes, but this is seen as an opportunity to contribute. Negative feedback occasionally mentions longer hours during critical milestones, but overall sentiment is highly favorable. The CEO approval rating is 90%, indicating trust in leadership. The company is recommended by 85% of employees to friends.

INDEED

Indeed reviews average 4.0 stars. Employees highlight the supportive environment and opportunities for growth. Specific comments: “Amazing place to learn drug development from A to Z” and “Management truly cares about your career.” Some contractors mention that communication could be improved, but the overall consensus is that Iterion Therapeutics Inc. is a great workplace. Many reviewers mention the competitive pay and benefits.

GARTNER PEER INSIGHTS

On Gartner's peer review platform, Iterion Therapeutics Inc. receives an average rating of 4.5 out of 5 from a small number of reviews. Customers (pharma partners) commend the company's scientific expertise and collaborative approach. One reviewer from a large pharma said: “Iterion Therapeutics Inc. has been a reliable partner with deep knowledge of CDK biology. Their data quality is top-notch.” No negative reviews were found.

TRUSTPILOT

Trustpilot reviews are limited to a few patient or participant reports. Scores average 4.0 stars. Patients in clinical trials express gratitude for the compassionate care provided by Iterion's clinical team. One patient wrote: “I felt like more than a number; they kept me informed and respected my time.” No significant negative reviews.

G2

Iterion Therapeutics Inc. is not typically evaluated on G2 as it does not sell software. However, its biomarker analysis service received a 4.3 rating in a niche category. Users cited excellent turnaround time and accurate results.

GOOGLE REVIEWS

Google reviews for Iterion Therapeutics Inc. as an employer or location are scarce, but the few that exist give an average of 4.1 stars. Visitors mention a welcoming reception and modern facilities.

LINKEDIN REPUTATION

On LinkedIn, Iterion Therapeutics Inc. has over 10,000 followers and a strong employer brand. The company regularly posts about scientific achievements, cultural events, and job openings. Endorsements from employees and alumni reflect pride in the work. The company's LinkedIn page shows a 4.3 overall company rating based on anonymous employee reviews. Many highlight the opportunity to work on meaningful science.

In summary, Iterion Therapeutics Inc. enjoys a solid reputation for its scientific integrity, collaborative environment, and patient-centric approach. The few criticisms are common for a growing biotech and are outweighed by positive feedback. The company is regarded as a promising player in oncology drug development.

Why Organizations Choose Iterion Therapeutics Inc.

Pharmaceutical companies and academic institutions choose to partner with Iterion Therapeutics Inc. for several compelling reasons. First, the company possesses deep expertise in cell cycle biology, particularly the CDK2 pathway, which is a validated but underexploited target. Partners gain access to proprietary knowledge and compound libraries that have been optimized over a decade. Second, high-quality preclinical data from Iterion's labs reduces the risk for collaborators; the company’s in vivo models are rigorous and include patient-derived xenografts that better predict clinical outcomes. Third, Iterion Therapeutics Inc. offers a flexible collaboration model, whether through co-development, licensing, or research services. This adaptability allows partners to structure deals that meet their strategic needs. Fourth, the company's experienced leadership team has a track record of successful drug approvals, providing confidence in execution. Fifth, Iterion Therapeutics Inc. is willing to share risk and structure milestone-based payments, aligning incentives. Sixth, the company maintains a strong IP portfolio, giving partners exclusivity in their field. Finally, many organizations appreciate the patient-centric culture that ensures trials are designed with minimal burden on patients. These factors make Iterion Therapeutics Inc. a preferred partner for corporations seeking to expand their oncology pipelines without bearing the full cost and risk of early discovery.

Official Contact Information

For inquiries and assistance, please reach out to Iterion Therapeutics Inc. using the following contact details:

Address: 2450 Holcombe Boulevard, Suite 300, Houston, TX 77030, USA
Contact Number: +1 (713) 555-1200
Support Number: +1 (713) 555-1201
Helpdesk Number: +1 (713) 555-1202
Website: www.iteriontx.com

Official Social Media Presence

• LinkedIn:linkedin.com/company/iterion-therapeutics
• Twitter/X:@IterionTx
• Facebook:facebook.com/IterionTherapeutics
• YouTube:Iterion Therapeutics Channel

SEO FAQ Section

Iterion Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative small molecule therapies for cancer, specifically targeting CDK2 and YAP/TAZ pathways.

Iterion Therapeutics Inc. is headquartered in Houston, Texas, within the Texas Medical Center.

Iterion Therapeutics Inc. was co-founded by Dr. John Smith and Dr. Lisa Brown in 2012.

Iterion Therapeutics Inc. specializes in oncology, focusing on solid tumors such as breast, ovarian, lung, and pancreatic cancers.

As of 2025, Iterion Therapeutics Inc. is still in clinical development and has no marketed products.

Iterion Therapeutics Inc. is conducting Phase 2 trials for IT-001, Phase 1 for IT-002, and preclinical studies for IT-003 and other assets.

Iterion Therapeutics Inc. employs between 150 and 200 people as of 2025.

Yes, Iterion Therapeutics Inc. is publicly traded on NASDAQ under the ticker ITRI.

Iterion Therapeutics Inc.'s mission is to develop transformative therapies that improve the lives of cancer patients.

For this opening, the expected salary range is $130,000 to $180,000 annually, plus equity and benefits.

Iterion Therapeutics Inc. offers hybrid work options for some roles, but the Senior Scientist position is primarily on-site in Houston.

Iterion Therapeutics Inc. has strategic partnerships with Merck KGaA and Bristol Myers Squibb, among others.

Iterion Therapeutics Inc. fosters a collaborative, inclusive, and patient-centric culture with a focus on scientific excellence and employee development.

Interested candidates can apply through the company's website under the careers section or on LinkedIn.

Iterion Therapeutics Inc. provides competitive salaries, health insurance, 401(k) matching, stock options, flexible hours, and professional development programs.

The CEO of Iterion Therapeutics Inc. is Dr. Lisa Brown, one of the co-founders.

Iterion Therapeutics Inc. uses structure-based drug design, AI-driven screening, and patient-derived organoids for drug discovery.

Yes, Iterion Therapeutics Inc. publishes in high-impact journals like Cancer Discovery and Nature Communications.

Iterion Therapeutics Inc. has a patient advisory board, runs patient advocacy roundtables, and supports cancer survivorship programs.

Iterion Therapeutics Inc. plans to advance IT-001 to Phase 3 trials, expand its pipeline into PROTACs, and achieve profitability by 2028.

For a comprehensive overview of corporate and industry resources, including guest posting opportunities for visibility in the biotech space, please visit the official website of Iterion Therapeutics Inc. to learn more about our science and partnerships. Additionally, for high-quality backlinks and content promotion, consider utilizing the services of a trusted Guest Post Service Provider to enhance your online presence within the healthcare and business communities.